P Berlanga1,2, V Segura3, A Juan Ribelles4,3, P Sánchez de Toledo5, T Acha6, V Castel3, A Cañete4,3. 1. Paediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain. berlanga_pab@gva.es. 2. Instituto de Investigación Sanitaria La Fe, Valencia, Spain. berlanga_pab@gva.es. 3. Instituto de Investigación Sanitaria La Fe, Valencia, Spain. 4. Paediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, Valencia, Spain. 5. Paediatric Oncology Unit, Hospital Universitario Vall d'Hebron, Barcelona, Spain. 6. Paediatric Oncology Unit, Hospital Carlos Haya, Málaga, Spain.
Abstract
PURPOSE: Multidisciplinary tumour boards (MDTs) are conducted worldwide for the management of patients with cancer, and they deliver a higher standard of care by simultaneously involving different specialists in diagnosis and treatment planning. However, information of paediatric MDTs functioning is scarce. A pilot study was conducted in Spain in the frame of the European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment (ExPO-r-Net). METHODS: A specific questionnaire was designed regarding various features of MDT practice. Data collected included information on the centres and the team, infrastructure for meetings, MDT organization/logistics and clinical decision-making. The survey was distributed to all Paediatric Oncology Units that register patients in the Spanish Registry of Childhood Tumours (RETI-SEHOP). RESULTS: 32 out of 43 contacted centres responded the questionnaire (74 % response rate; 88 % response rate for centres with >25 new patients/year). All units with >25 new patients/year have a dedicated Paediatric MDT compared to 76 % of units with ≤25 new patients/year. MDTs should be improved at institutional level by clear protected time in service planning for all specialists involved, incentives for attendance and attendance registration. Clinical decision-making process and follow-up of recommendation adherence should be assessed and potential legal responsibilities for physicians participating in Tumour Board defined. Network collaboration through virtual MDTs, using available videoconferencing tools, is an opportunity to share expertise among centres.
PURPOSE:Multidisciplinary tumour boards (MDTs) are conducted worldwide for the management of patients with cancer, and they deliver a higher standard of care by simultaneously involving different specialists in diagnosis and treatment planning. However, information of paediatric MDTs functioning is scarce. A pilot study was conducted in Spain in the frame of the European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment (ExPO-r-Net). METHODS: A specific questionnaire was designed regarding various features of MDT practice. Data collected included information on the centres and the team, infrastructure for meetings, MDT organization/logistics and clinical decision-making. The survey was distributed to all Paediatric Oncology Units that register patients in the Spanish Registry of Childhood Tumours (RETI-SEHOP). RESULTS: 32 out of 43 contacted centres responded the questionnaire (74 % response rate; 88 % response rate for centres with >25 new patients/year). All units with >25 new patients/year have a dedicated Paediatric MDT compared to 76 % of units with ≤25 new patients/year. MDTs should be improved at institutional level by clear protected time in service planning for all specialists involved, incentives for attendance and attendance registration. Clinical decision-making process and follow-up of recommendation adherence should be assessed and potential legal responsibilities for physicians participating in Tumour Board defined. Network collaboration through virtual MDTs, using available videoconferencing tools, is an opportunity to share expertise among centres.
Authors: Rozh Jalil; Waseem Akhter; Benjamin W Lamb; Cath Taylor; Jenny Harris; James S A Green; Nick Sevdalis Journal: J Urol Date: 2014-03-11 Impact factor: 7.450
Authors: Benjamin W Lamb; Katrina F Brown; Kamal Nagpal; Charles Vincent; James S A Green; Nick Sevdalis Journal: Ann Surg Oncol Date: 2011-03-26 Impact factor: 5.344
Authors: A Juan Ribelles; P Berlanga; G Schreier; M Nitzlnader; B Brunmair; V Castel; S Essiaf; A Cañete; R Ladenstein Journal: Clin Transl Oncol Date: 2018-01-08 Impact factor: 3.405
Authors: Mercedes Guilabert; Joan Prades; Josep M Borras; Inmaculada Maestu; Juan Antonio Guerra; Lluís Fumadó; José Joaquin Mira Journal: J Med Internet Res Date: 2022-03-10 Impact factor: 7.076